BMJ:同父异母或同母异父兄弟姐妹家族结肠癌风险研究

2019-03-19 MedSci MedSci原创

研究发现,结直肠癌家族风险对于同父异母或同母异父的兄弟姐妹仍十分显著,除父母兄弟姐妹外,其他二级结肠癌亲属导致的结肠癌风险可忽略不计

近日研究人员就直肠癌患者家属的直肠癌风险进行了考察,重点研究二级亲属,尤其是同父异母或同母异父兄弟姐妹(半同胞)亚组的风险。

1931年后出生的1600万瑞典人参与研究,随访期从1958年至2015年,其中结肠癌患者173796人,研究的主要终点为0-79岁人群,一级和二级亲属结直肠癌的累积风险和标准化发病率。

CRC患者其亲属的累积结肠癌风险为7%,与无结肠癌家族史人群相比,其风险增加1.7倍,伴同胞的累积风险也较高(标准化事件风险1.5)。对于父母以及半同胞均为结肠癌患者的人群(n=32),以及父母以及同父同母同胞均为结肠癌患者的人群(n=396),其结肠癌风险均就显著增加(标准化事件风险3.6 vs 2.7)。对于非父母系结肠癌亲属,如祖父母、舅舅或姑姑,结直肠癌家族风险的影响降低。

研究发现,结直肠癌家族风险对于同父异母或同母异父的兄弟姐妹仍十分显著,除父母兄弟姐妹外,其他二级结肠癌亲属导致的结肠癌风险可忽略不计。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2055656, encodeId=6aa8205565617, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Jun 09 00:07:00 CST 2019, time=2019-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061836, encodeId=0604206183669, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sat Dec 21 20:07:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848707, encodeId=20b21848e0717, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Thu May 16 14:07:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363203, encodeId=8d813632034c, content=好文章,点赞啦!认真学习,谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Tue Mar 19 16:25:11 CST 2019, time=2019-03-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2055656, encodeId=6aa8205565617, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Jun 09 00:07:00 CST 2019, time=2019-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061836, encodeId=0604206183669, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sat Dec 21 20:07:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848707, encodeId=20b21848e0717, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Thu May 16 14:07:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363203, encodeId=8d813632034c, content=好文章,点赞啦!认真学习,谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Tue Mar 19 16:25:11 CST 2019, time=2019-03-19, status=1, ipAttribution=)]
    2019-12-21 sjq027
  3. [GetPortalCommentsPageByObjectIdResponse(id=2055656, encodeId=6aa8205565617, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Jun 09 00:07:00 CST 2019, time=2019-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061836, encodeId=0604206183669, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sat Dec 21 20:07:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848707, encodeId=20b21848e0717, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Thu May 16 14:07:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363203, encodeId=8d813632034c, content=好文章,点赞啦!认真学习,谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Tue Mar 19 16:25:11 CST 2019, time=2019-03-19, status=1, ipAttribution=)]
    2019-05-16 gaoxiaoe
  4. [GetPortalCommentsPageByObjectIdResponse(id=2055656, encodeId=6aa8205565617, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Jun 09 00:07:00 CST 2019, time=2019-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061836, encodeId=0604206183669, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sat Dec 21 20:07:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848707, encodeId=20b21848e0717, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Thu May 16 14:07:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363203, encodeId=8d813632034c, content=好文章,点赞啦!认真学习,谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Tue Mar 19 16:25:11 CST 2019, time=2019-03-19, status=1, ipAttribution=)]
    2019-03-19 1dd8a7c5m95(暂无匿称)

    好文章,点赞啦!认真学习,谢谢分享给广大同好!

    0

相关资讯

做好这三招,大肠癌早期诊断不是梦

近年来,我国大肠癌的发病率呈逐年升高的趋势,而能够得到早期确诊的大肠癌患者却很少。在临床上,大肠癌的早期诊断率偏低,其原因主要是人们对该病的早期信号没有足够的重视。

Lancet Oncol:帕妥珠单抗联合曲妥珠单抗治疗HER2阳性结肠癌

研究认为帕妥珠单抗联合曲妥珠单抗是治疗HER2-扩增转移性结直肠癌的有效手段

一场关于结直肠癌肝转移治疗后复发的“圆桌对话”

肝脏是结直肠癌转移最主要的靶器官,结直肠癌肝转移(CRLM)患者通过以手术为主的综合治疗能够获得长期生存甚至治愈。但是,CRLM治疗后复发是临床上面临的难点,也是影响患者预后的主要原因。

Radiology: 胸部CT在各期结肠癌患者胸部转移的诊断价值

本研究旨在基于结肠癌患者对比增强腹部CT临床分级,测量分级对比增强胸部CT的诊断率和错误转诊率(FRR)。

Gastroenterology:炎症性肠病后息肉患者结肠癌风险评估

研究认为,炎症性肠病后息肉患者其结直肠肿瘤风险与一般IBD患者相当,但结肠切除率增加

GUT:粪便免疫与结肠镜对中度结肠癌风险人群筛查效果比较研究

研究认为,对于中等结肠癌风险人群,采用粪便免疫化学法进行定期筛查可减少71%的筛查次数,大幅降低筛查费用,但检查敏感性有所下降